You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Computerizing NIAAA's Best Practices for Youth Screening and Brief Intervention
SBC: COG ANALYTICS, LLC Topic: 400DESCRIPTION provided by applicant The early onset of alcohol misuse during adolescence is a widespread problem in the U S Studies have consistently documented both the short and long term adverse neurophysiological impacts and health risk behaviors associated with alcohol misuse during adolescence Given the magnitude of this problem and its myriad consequences preventing early initiation of ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Mobile Intervention Kit to Increase HIV/HCV Testing and Overdose Prevention Training
SBC: Digital Health Empowerment, Inc Topic: NIDADESCRIPTION provided by applicant Because many people who inject drugs PWID do not receive adequate information about HIV or HCV testing and prevention or overdose prevention and response training we propose to develop a Mobile Intervention Kit to deliver technology based interventions from a library of theory guided video content The first iteration will address overdose prevention and r ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Targeted Epigenetic Therapy for Triple-Negative Breast Cancer
SBC: PARKSIDE SCIENTIFIC INC. Topic: 102DESCRIPTIONprovided by applicantTriple negative breast cancerTNBCis one of the most aggressive forms of human cancerand currently has no targeted therapyChemotherapy is the only available treatment for TNBC patientsbut is deleterious and not effective once tumor spreadsTNBC represents a major unmet medical needaboutof breast cancer incidenceswomen worldwide inare TNBCTNBC disproportionally affects ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Effectiveness of VBP15, a dissociative steroidal analogue, on chronic inflammation in a mouse model of multiple sclerosis
SBC: REVERAGEN BIOPHARMA, INC. Topic: NIAIDDESCRIPTION provided by applicant Glucocorticoids GCandapos s such as prednisolone are used frequently to induce remission and treat multiple sclerosis MS Despite effectiveness many GC mediated detrimental side effects including osteoporosis and muscle atrophy limit long term chronic treatment of MS patients These side effects are believed to be mediated by well described glucocorticoi ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists
SBC: Bohemica Pharmaceuticals, LLC Topic: 100DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Engineering stem cells to make mucopolysaccharidosis IIIB
SBC: Phoenix Nest Inc. Topic: 107DESCRIPTION provided by applicant Sanfilippo disease type B also called mucopolysaccharidosis type III or MPS III is a devastating neuro degenerative genetic disorder of childhood that is fatal There is no cure or effective treatment MPS IIIB is caused by the lack of a lysosomal enzyme called NAGLU alpha N acetylglucosaminidase that is required to degrade heparan sulfate glycosaminoglyca ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Mutation Enriched Targeted Re Sequencing
SBC: TRANSGENOMIC, INC. Topic: 103DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Validation of a salivary miRNA diagnostic test for autism spectrum disorder
SBC: Quadrant Biosciences Inc. Topic: 105Project Summary Abstract Autism spectrum disorder ASD is a continuum of neurodevelopmental characteristics that includes deficits in communication and social interaction as well as restrictive repetitive interests and behaviors ASD is an increasing public health concern with about in American children diagnosed with ASD in a fold increase in prevalence over the past years T ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Smaller, Brighter Probes for Correlative Super-resolution and Electron Microscopy
SBC: NANOPROBES INC Topic: NIGMSDESCRIPTION provided by applicant We propose new probes for correlative super resolution fluorescence and electron microscopy that use biorthogonal reactions Click SNAP and HALO tags to label targets in living cells To minimize quenching of the fluorophores by the gold particles the small Undecagold gold atoms gold cluster label will be used this has minimal absorption at wavelengt ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Immuno-CometChip for Human Skin Basal Cell Genotoxicity Testing
SBC: TREVIGEN, INC. Topic: 113DESCRIPTION provided by applicant The objective of this Phase STTR research is to quantify genotoxicity in basal cell keratinocytes from organotypic cultures Epiderm in response to commonly used chemical agents The proposed product is a Comet Chip assay that measures DNA damage in basal cells derived from a reconstructed human epidermis Technical questions that will be addressed are Ca ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health